Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin’s lymphoma: a cohort study of the French national health insurance database

Conte, Cécile; Rueter, Manuela; Laurent, Guy; Bourrel, Robert; Lapeyre‐Mestre, Maryse; Despas, Fabien

doi:10.1007/s00520-016-3331-y

Cited by 13 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pattern of PD consumption found in our study is in agreement with the French PD consumption around a cancer diagnosis: In a nationwide claim database study aiming to determine the PD use in solid cancer and lymphoma, 32.1% of patients had a prevalent PD consumption during the year before the diagnosis, vs. 52.6% during the year following this diagnosis, of which anxiolytics were the most frequent . Similarly, one French study in Midi‐Pyrénées found a PD use of 32.2% in patients having a B‐cell lymphoma diagnosed, anxiolytics being the most PD used .…”

Section: Discussionsupporting

confidence: 86%

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Gauthier

Conte

Palmaro

et al. 2020

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Psychotropic drugs (PD) are often used close to a cancer diagnosis and may be considered as a way of coping. We aimed to determine the incidence of anxiolytics, hypnotics, antidepressants, and antipsychotics initiation around a diagnosis of chronic myelogenous leukemia (CML). Population‐based cohort: Data were extracted from Systeme National des données de Santé (SNDS, the French health insurance database) at the regional level (Midi‐Pyrenees area, 2.9 million inhabitants). All newly diagnosed patients treated by a CML tyrosine kinase inhibitor (TKI) between 10/01/2011 and 04/01/2014 were included. Pre‐CML (9 months before to 3 months before first TKI prescription—F‐TKI) and CML (3 months before to 9 months after F‐TKI) phases were defined. The main evaluation criterion was the initiation of PD during CML phase. Determinants associated with this incident PD use were studied through a logistic regression model. We compared pre‐CML and CML healthcare consumption. The cohort included 103 patients (mean age of 60.8 years). PD initiation rate was 35.9%, anxiolytics being the most initiated PD (59.5%). Advanced age was associated with PD initiation (adjusted OR = 1.029, 95% CI = 1.001–1.056). The number of consultations during the pre‐CML phase and female gender tended to be associated with increased risk of PD initiation in univariate analysis. For PD initiators, healthcare consumption was greater in CML but not in pre‐CML phase. PD initiation is a frequent finding around a CML diagnosis. Its risk increases with age. It could be a way to identify a subgroup with higher healthcare consumption.

show abstract

Section: Discussionsupporting

confidence: 86%

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Gauthier

Conte

Palmaro

et al. 2020

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conte et al investigated the incidence of depression and anxiety using an approach similar to that of the present study with incident use of PDs as measures for depression and anxiety 13 . In total, 745 NHL patients (mean age 65.1 years, male:female ratio 1.4) were included, and incident PD use was estimated during first 8 months after diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators

et al. 2022

View full text Add to dashboard Cite

Psychological distress following cancer diagnosis may lead to mental health complications including depression and anxiety. Non-Hodgkin lymphomas (NHLs) include indolent and aggressive subtypes for which treatment and prognosis differ widely.Incident use of psychotropic drugs (PDs-antidepressants, antipsychotics, and anxiolytics) and its correlation to lymphoma types can give insights into the psychological distress these patients endure. In this prospective matched cohort study, we used nationwide population-based registries to investigate the cumulative risk of PD use in NHL patients compared to a sex-and age-matched cohort from the Danish

show abstract

“…These findings are in line with a smaller French study investigating the incidence of psychotropic drug use during the diagnosis and active treatment phase in patients with B-NHL. Here, among 745 newly diagnosed B-NHL patients with a mean age of 65.1 years, psychotropic treatment—reflecting the possible prevalence of depression or anxiety disorders—was initiated in 31.5 %, compared to 7.6% in the general population during the same period [ 18 ]. Another study conducted by Oerlemans et al analyzed data of 489 patients with HL or DLBCL who serially completed the Hamilton Anxiety and Depression Scale [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany

Tilch

Galle

Schattenberg

et al. 2021

Support Care Cancer

View full text Add to dashboard Cite

Purpose The aim of this study was to explore the incidence of depression and anxiety disorder diagnoses in a large German cohort of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) diagnoses in comparison to patients without cancer over a 10-year time frame. Methods Patients with HL (n=687) and NHL (n=4130) were matched to cohorts without a cancer diagnosis (n=687 and 4130) by age, sex, and yearly consultation frequency. The primary outcome of the study was the incidence of depression and anxiety disorders. The relationship between lymphoma, separated into HL and NHL, and both depression and anxiety disorders was investigated using Cox regression models. Results We compared 687 patients with HL with 687 matched non-cancer individuals and 4130 patients with NHL with 4130 matched non-cancer individuals. Within 10 years of the index date, 24.0% of patients with HL and 22.3% of patients with NHL were diagnosed with depression. Anxiety disorders were diagnosed in 6.7% and 5.3% of patients with HL and NHL, respectively. On regression analyses, HL (HR 2.30, 95% CI 1.65–3.21, p<0.001) and NHL (HR 2.09, 95% CI 1.81–2.41, p<0.001) were positively associated with incident depression. The HR for anxiety disorders was 1.64 (95% CI 1.24–2.16, p<0.001) in patients with NHL, while HL was not associated with incident anxiety disorders (HR 1.21, 95% CI 0.71–2.07, p<0.478). Conclusion Lymphoma constitutes a risk factor for emerging depression and anxiety disorders. Following the diagnosis of lymphoma, screening and strategies to prevent the occurrence of these diseases seem warranted.

show abstract

Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin’s lymphoma: a cohort study of the French national health insurance database

Abstract: The high rate of psychotropic drug initiation reflects a high level of anxiety at the initial phase of B-NHL patients' trajectory. This pharmacoepidemiological study reveals inappropriate use in some patients, which should now be investigated in lymphoma survivorship.

Cited by 13 publications

References 27 publications

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators

Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany

Contact Info

Product

Resources

About